期刊文献+

左西孟旦在左心室功能低下患者不停跳冠状动脉旁路移植术中的应用 被引量:3

Clinical effects of levosimendan in patients with left ventricular systolic dysfunction under off-pump coronary artery bypass grafting
下载PDF
导出
摘要 目的:探讨左西孟旦对左心室收缩功能低下患者在不停跳冠状动脉旁路移植术(CABG)中心肌保护效果。方法:本院心外科在2010年5月至2012年11月,抽取术前左室射血分数小于45%的CABG病例40例,随机分为试验组和对照组各20例,对照组在手术中开始应用多巴胺静脉维持泵入,试验组同期加用左西孟旦,初始负荷量为10μg/kg,注射时间10min,随即以0.1~0.2μg·kg-1·min-1起泵入持续23h。记录两组患者治疗后监护室滞留时间、房颤发生率、多巴胺治疗时间、30d死亡率、记录手术后前3d的床边心脏超声测量左心室射血分数(LVEF)值比较,以及手术后早期ICU即刻(0)、术后6、24、48h的肌钙蛋白I(cTnI)指标变化。结果:试验组和对照组均无死亡病例。与对照组比较,试验组患者手术后多巴胺治疗时间缩短(P<0.05),房颤发生率降低(P<0.05)。术后6h和24h试验组的cTnI指标低于对照组(P<0.05)。试验组第1、2天LVEF指标高于对照组(P<0.05)。其余无统计学差异(P>0.05)。结论:左西孟旦对于术前左心室收缩功能低下的CABG患者具有一定心肌保护作用。 To effect of levosimendan in investigate the clinical patients with lower left ventricular eject fraction (LVEF) under of pump coronary artery bypass grafting (CABG). METHODS: From May 2010 to November 2012, 40 cases with lower LVEF below 45 undergo ing elective CABG were randomly derided into treatment group (20 cases) and control group (20 cases). All the cases received dopamine treatment perioperatively, and levosimendan were additionally used in the treatment group. The ICU time, the incidence of atrial fibrillation (AF) ,the duration of dopamine use, the mortal ity in the first 30 days were recorded. The level of LVEF in the first 3 days and the cTnI at 0,6, 24,48 h after the operation were examined. RE SULTS:No case died in both groups. Comparingwith control group, treatment group had lower incidence of AF (P〈0. 05), and shorter time of dopamine use (P〈0.05). Treatment group had a higher LVEF in the first two days than those in control group (P〈0.05). Treatment group had lower cTnI at the 6h and 24h time point af ter the operation than those in control group(P 〈0.05). There was no remarkable difference between two groups in other aspects. CONCLU- SION: Levosimendan has cardiac protection effect on patients under CABG with lower LVEF.
出处 《中国临床药理学与治疗学》 CAS CSCD 2013年第10期1160-1163,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 左西孟旦 心脏手术 冠脉旁路移植术 左心室射血分数 收缩功能低下 KEY WORDS Levosimendan Cardiac surgery Coronary artery bypass grafting Left ventricularejection fraction Systolic dysfunction
  • 相关文献

参考文献16

  • 1Christakis GT, Fremes SE, Naylor CD, et al. Im pact of preoperative risk and perioperative morbidity on ICU stay following coronary bypass surgery[J]. Cardiovasc Surg,1996, 4(1): 29- 35.
  • 2De Santis V, Vitale D, Tritapepe L, et al. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome [J]. Ann Intern Med, 2008,149(5) : 365-367.
  • 3Moiseyev VS, Poder P, Andreievs N, et al. Safety and efficacy of a novel calcium sensitizer, levosi mendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo controlled, doubleblind study (RUSSLAN) [J]. Eur Heart J, 2002,23(18): 1422-1432.
  • 4Russ MA, Prondzinsky R, Christoph A, et al. He- modynamic improvement following levosimendan treatment in patients with acute myocardial infarc tion and cardiogenic shock [J]. Crit Care Med, 2007,35(12): 2732 -2739.
  • 5Lehmann A, Lang J, Boldt J, et al. I.evosimendan in patients with cardiogenic shock undergoing surgi cal revascularization: a case series [J]. Med Sci Monit, 2002, 10(8):MT89-MT93.
  • 6Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic res- onance study[J]. J Biol Chem, 1994, 269 (46): 28584-28590.
  • 7Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan , a new positive inotropic drug, de creases myocardial infarct size via activation of KATV channels[J]. Anesth Analg, 2000, 90(1) : 5-11.
  • 8Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocar- dial ischemina[J]. J Am Coll Cardiol, 2004, 43 ( 12) : 2177-2182.
  • 9Kaheinen P, Pollesello P, Levijoki J, et al. Effects of levosimendan and milrinone on oxygen consump- tion in isolated guinea-pig heart[J]. J Cardiovasc Pharmacol, 2004, 43(4) : 555-561.
  • 10Michaels AD, Mckeown B, Kostal M, et al. Effects of intravenous levosimendan on human cor- onary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake [J].Circu- lation, 2005, 111(12) : 1504- 1509.

二级参考文献48

  • 1施旖旎,黄子通,蒋龙元,王彤.乌司他丁治疗全身炎症反应综合征的临床研究[J].中国急救医学,2004,24(10):738-739. 被引量:37
  • 2吴洪斌,宋云虎,胡盛寿.左心室收缩功能低下冠心病病人冠状动脉旁路移植术的中远期效果[J].中华胸心血管外科杂志,2005,21(3):139-141. 被引量:7
  • 3Pagel PS, Harkin CP, Hettrick DA, et al.Levosimendan (OR-1259), a myofilament calcicum sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs[ J ] .Anesthesiology, 1994,81: 947-978.
  • 4Lehtonen L, P o der P.The utility of levosimendan in the treatment of heart failure[ J ] .Ann Med,2007,39 ( 1 ): 2-17.
  • 5Kota B, Prasad AS, Economides C, et al. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure[ J ] .J Cardiovasc Pharmacol Ther, 2008, 13 ( 4): 269-278.
  • 6Silva-Cardoso J, Ferreira J, Oliveira--Soares A, et al. Effectiveness and safety of levosimendan in clinical practice[ J ] .Rev Port Cardiol, 2009,28 ( 2 ): 143-154.
  • 7Tagarakis GI, Tsilimingas NB.Levosimendan for heart-operated patients: what is the state of the art[ J ] .Recent Pat Cardiovase Drug Discov, 2009,4 ( 1 ): 22-24.
  • 8Garcia-Gonzalez MJ, Dominguez-Rodriguez A.New pharmacologic options in the treatment of acute coronary syndromes and myocardial ischemia-reperfusion injury: potential role of levosimendan [ J ] .Minerxi Cardioangiol, 2007,55 ( 5 ): 625-635.
  • 9Cianfrocca C, Pelliccia F, Pasceri V, et al. Strain rate analysis and levosimendan improve detection of myocardial viability by dobutamine echocardiography in patients with post-infarction left ventrieular dysfunction: a pilot stdy[ J ] .J Am Soc Echocardiogr, 2008,21 (9): 1068-1074.
  • 10Franklin F.Owinsgs, Margaret Fox, Conrad J.Kowalski, et al. An Enantioselective Synthesis of SK&F93505, a Key Intermediate for Preparing Cardiotonic Agents[ J ] .J Org Chem, 1991,56: 1963-1966.

共引文献54

同被引文献25

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部